
SRRK Stock Forecast & Price Target
SRRK Analyst Ratings
Bulls say
Scholar Rock Holding Corp demonstrates a positive outlook due to the encouraging Phase 3 SAPPHIRE data, which supports the likelihood of regulatory approval and potential commercial success, particularly in expanding its label for SMA treatment. The company's shares have increased by approximately 4%, reflecting market confidence, and analysts note that SRRK is trading at about 14x net cash, highlighting its perceived undervaluation and favorable risk/reward profile over the next 12-24 months. Furthermore, management has indicated successful resolutions to previous observations at their contract development and manufacturing organization (CDMO) facility, suggesting a strengthened operational foundation moving forward.
Bears say
Scholar Rock Holding Corp faces a negative outlook primarily due to the significant delay in the anticipated commercial launch of its lead product, apitegromab, which has been pushed back from the fourth quarter of 2025 to the second quarter of 2026 for the US and from the second quarter of 2026 to the third quarter of 2026 for the EU. This setback has resulted in a revised peak sales estimate of $1.7 billion by 2035, reflecting increased competitive risks and a potential new standard of care emerging in the near term. Additionally, the issuance of a Complete Response Letter (CRL) introduces further regulatory and pricing uncertainties, which raise concerns about SRK-181's market viability and the overall risk/benefit profile in ongoing and future indications.
This aggregate rating is based on analysts' research of Scholar Rock Holding Corp and is not a guaranteed prediction by Public.com or investment advice.
SRRK Analyst Forecast & Price Prediction
Start investing in SRRK
Order type
Buy in
Order amount
Est. shares
0 shares